Arcus kidney cancer drug casdatifan impresses analysts, lifting shares 8%
Start here
At a research and development day, Arcus Biosciences presented follow-up data on casdatifan, its investigational drug for kidney cancer. Analysts who reviewed the results believe the candidate's efficacy may be superior to that of Merck's marketed drug Welireg, which targets the same disease. Investor reaction was positive: Arcus shares rose 8% on the day of the presentation. The data strengthen the company's competitive position in kidney cancer, though the candidate remains in development rather than on the market. Separate from the data, the event coincided with deal news involving TriGemX, which announced a SPAC transaction. How casdatifan performs against Welireg in later-stage testing and how the TriGemX SPAC deal proceeds are the open questions.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- BioPharma DiveArcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
At its R&D day, Arcus Biosciences presented follow-up data on casdatifan, its kidney cancer drug candidate. Analysts believe its efficacy may be superior to Merck's marketed drug Welireg, and the company's shares rose 8% that day.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 23:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.